3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Tumor-Agnostic
1
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gastrointestinal
1
Conditions
Breast Neoplasms
2
Interventions
Trastuzumab
260
Paclitaxel
216
Cyclophosphamide
173
Docetaxel
146
Letrozole
126
Fulvestrant
121
Capecitabine
121
Doxorubicin
111
Carboplatin
98
Bevacizumab
90
exemestane
88
Anastrozole
85
Tamoxifen
77
Lapatinib
77
pembrolizumab
68
Albumin-Bound Paclitaxel
67
pertuzumab
62
palbociclib
60
Taxes
59
Gemcitabine
57
eribulin
48
130-nm albumin-bound paclitaxel
47
Radiotherapy
46
Everolimus
44
Ado-Trastuzumab Emtansine
43
Vinorelbine
39
ixabepilone
32
Epirubicin
30
Cisplatin
30
pegfilgrastim
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
AZD4547
×
Breast
×
Clear all
NCT01791985
2022-08-22
RADICAL
Imperial College London
Phase 1/2
Completed
52 enrolled
17 charts
NCT01202591
2016-02-11
GLOW
AstraZeneca
Phase 1/2
Completed
127 enrolled
8 charts